首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   17814篇
  免费   1356篇
  国内免费   500篇
耳鼻咽喉   13篇
儿科学   2163篇
妇产科学   71篇
基础医学   1538篇
口腔科学   52篇
临床医学   2332篇
内科学   3445篇
皮肤病学   153篇
神经病学   150篇
特种医学   184篇
外国民族医学   5篇
外科学   189篇
综合类   2764篇
预防医学   378篇
眼科学   54篇
药学   1287篇
  7篇
中国医学   295篇
肿瘤学   4590篇
  2023年   255篇
  2022年   262篇
  2021年   520篇
  2020年   612篇
  2019年   549篇
  2018年   499篇
  2017年   578篇
  2016年   538篇
  2015年   644篇
  2014年   1087篇
  2013年   1161篇
  2012年   877篇
  2011年   1085篇
  2010年   758篇
  2009年   782篇
  2008年   776篇
  2007年   739篇
  2006年   701篇
  2005年   674篇
  2004年   671篇
  2003年   496篇
  2002年   439篇
  2001年   437篇
  2000年   313篇
  1999年   300篇
  1998年   263篇
  1997年   184篇
  1996年   260篇
  1995年   315篇
  1994年   290篇
  1993年   260篇
  1992年   248篇
  1991年   224篇
  1990年   175篇
  1989年   187篇
  1988年   182篇
  1987年   134篇
  1986年   114篇
  1985年   215篇
  1984年   167篇
  1983年   106篇
  1982年   133篇
  1981年   104篇
  1980年   83篇
  1979年   91篇
  1978年   61篇
  1977年   48篇
  1976年   46篇
  1975年   13篇
  1974年   7篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals.  相似文献   
3.
ObjectiveThere is a paucity of data concerning the use of granulocyte colony-stimulating factors (G-CSFs) in pediatric patients with acute lymphoblastic leukemia (ALL). The aim of the present study was to evaluate the effect of G-CSF use on relapse-free and overall survival in 358 consecutive, newly diagnosed pediatric ALL patients uniformly treated at the same institution between April 2012 and April 2020.Materials and MethodsPatients were evaluated in two separate periods, based on the G-CSF treatment approach. All patients who underwent ALL treatment between April 2012 and December 2016 received G-CSF (G-CSF+ arm; n: 245) in the course of the protocol for reducing the risk of febrile neutropenia and/or inducing neutrophil recovery to prevent any treatment delay. No patients after December 2016 received G-CSF, even if they belonged to the high-risk group, and these were included in the G-CSF? arm (n: 113).ResultsEstimated mean relapse-free (106.5 months; 95 % CI 102?110.8 vs 82 months 95 % CI 75.2?88.9; p: 0.794) and overall survival (111.4 months; 95 % CI 108?114.8 vs 85 months 95 % CI 80.4?89.8; p: 0.431) rates were similar between the G-CSF+ and G-CSF? groups.ConclusionsOur findings indicate that G-CSF use during ALL treatment had no effect on relapse rates or overall survival.  相似文献   
4.
5.
6.
7.
8.
《Vaccine》2022,40(7):1001-1009
Vaccination guidelines for dogs and cats indicate that core vaccines (for dogs, rabies, distemper, adenovirus, parvovirus; for cats, feline parvovirus, herpes virus-1, calicivirus) are essential to maintain health, and that non-core vaccines be administered according to a clinician’s assessment of a pet’s risk of exposure and susceptibility to infection. A reliance on individual risk assessment introduces the potential for between-practice inconsistencies in non-core vaccine recommendations. A study was initiated to determine non-core vaccination rates of dogs (Leptospira, Borrelia burgdorferi, Bordetella bronchiseptica, canine influenza virus) and cats (feline leukemia virus) in patients current for core vaccines in veterinary practices across the United States. Transactional data for 5,531,866 dogs (1,670 practices) and 1,914,373 cats (1,661 practices) were retrieved from practice management systems for the period November 1, 2016 through January 1, 2020, deidentified and normalized. Non-core vaccination status was evaluated in 2,798,875 dogs and 788,772 cats that were core-vaccine current. Nationally, median clinic vaccination rates for dogs were highest for leptospirosis (70.5%) and B. bronchiseptica (68.7%), and much lower for canine influenza (4.8%). In Lyme-endemic states, the median clinic borreliosis vaccination rate was 51.8%. Feline leukemia median clinic vaccination rates were low for adult cats (34.6%) and for kittens and 1-year old cats (36.8%). Individual clinic vaccination rates ranged from 0 to 100% for leptospirosis, B. bronchiseptica and feline leukemia, 0–96% for canine influenza, and 0–94% for borreliosis. Wide variation in non-core vaccination rates between clinics in similar geographies indicates that factors other than disease risk are driving the use of non-core vaccines in pet dogs and cats, highlighting a need for veterinary practices to address gaps in patient protection. Failure to implement effective non-core vaccination strategies leaves susceptible dogs and cats unprotected against vaccine-preventable diseases.  相似文献   
9.
PI3K-AKT-mTOR通路是人体内重要的信号通路之一,其在控制细胞生长、分化、凋亡和自噬等方面都发挥着重要作用。近年来研究发现,PI3K-AKT-mTOR信号通路与急性髓系白血病(acute myeloid leukemia,AML)的发生发展密切相关。以PI3K-AKT-mTOR 通路为靶点的AML治疗也取得了很大进步。本文就PI3K-AKT-mTOR信号通路的组成、表达、调控以及该信号通路相关抑制剂在AML中的研究进展进行综述,并对今后的研究方向进行展望。  相似文献   
10.
BackgroundDespite high rate of cure in acute promyelocytic leukemia (APL) in clinical trials, outcomes in real-world practice are dismal. We utilized National Cancer Database (NCDB) to explore utilization of multiagent therapy in APL and identify any disparities in treatment in real-world practices.Patients and MethodsNCDB categorizes use of systemic chemotherapy into single agent versus multiagent therapy. Some patients received hormonal therapy, immunotherapy, and unknown therapy; details of these treatments could not be ascertained. We therefore used multiple logistic regression analysis to evaluate effects of covariates on the probability of multiagent therapy use in 6678 patients.ResultsCompared to patients >60 years, patients aged 0 to 18 years (hazard ratio[HR] 3.2, 95% confidence interval [CI] 1.8-5.5, P< .0001), 19 to 40 years (HR 1.6, 95% CI 1.03-2.54, P= .03), and 41 to 60 years (HR 1.6, 95% CI 1.3-1.9, P< .0001) were more likely to receive multiagent therapy. Patients with Charlson comorbidity index (CCI) of 0 (HR 1.6, 95% CI 1.2-2.3, P= .001) and CCI of 1 (HR 1.4, 95% CI 1.0-1.9, P= .04) had a higher likelihood of receiving multiagent therapy than patients with CCI ≥ 3. Patients treated at academic cancer centers, compared to those treated at community cancer center (HR 0.5, 95% CI 0.3-0.7, P= .001), comprehensive community cancer center (HR 0.7, 95% CI 0.6-0.8, P< .0001), and integrated network cancer center (HR 0.8, 95% CI 0.6-0.9, P= .02) were more likely to be treated with multiagent therapy. Compared to the patients with private insurance, those with Medicaid had increased likelihood (HR 1.2, 95% CI 1.0-1.4, P= .04) whereas uninsured patients had a lower likelihood of receiving multiagent therapy (HR 0.6, 95% CI 0.5-0.8, P= .0005).ConclusionTo our knowledge, this study is the first and the largest scale analysis of treatment practices in APL in real-world practices. Our findings highlight significant disparities in treatment of APL based on age, insurance, and health-system factors.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号